LMBio
Latest round
- Series A
Last raised
- Dec 2024
Total raised
- Undisclosed
Investors
- 3
About LMBio
Founded in 2020 and based in Suzhou, China, LMBio is a biotech company that focuses on the research and development of cellular immunotherapy products with TILs therapy as the core. Dr. Feng li, the company's CSO, worked in the TIL laboratory at the MD Anderson Cancer Research Center in the United States. The company's main product is TILS LM103 injection which release cytotoxin to directly kill tumor cells. The company generates revenue by providing cellular immunotherapy products focusing on tumor infiltrating lymphocytes (TILs) therapy.
Who invested in LMBio
3 investors across 2 rounds
See all investors in LMBio
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about LMBio
Who invested in LMBio?
LMBio has 3 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has LMBio raised?
LMBio has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did LMBio last raise money?
LMBio's most recent round on record is a Series A, in Dec 2024.
What does LMBio do?
Founded in 2020 and based in Suzhou, China, LMBio is a biotech company that focuses on the research and development of cellular immunotherapy products with TILs therapy as the core.
Where is LMBio headquartered?
LMBio is headquartered in Suzhou, China.
Which VCs invest in companies like LMBio?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at LMBio's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like LMBio? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.